Description: Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services. The company also provides early stage clinical/bioequivalence services; absolute bioavailability and human radiolabel studies; and chemistry services, including performing custom synthesis. It operates in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation operates as a subsidiary of Hongkong Tigermed Co., Limited.
Home Page: www.frontagelab.com
700 Pennsylvania Drive
Exton,
PA
19341
United States
Phone:
610 232 0100
Officers
Name | Title |
---|---|
Dr. Song Li Ph.D. | Founder & Chairman |
Dr. Abdul Ezaz Mutlib Ph.D. | Chief Executive Officer |
Mr. Jun Gao | CFO & President of Asia Pacific |
Mr. Richard Fischetti J.D. | VP & General Counsel of Frontage Labs |
Dr. Dongmei Wang Ph.D. | Executive Vice President of Global Sales & Marketing and Project Management |
Dr. Zhongping Lin Ph.D. | President of Frontage Labs |
Dr. Tianyi Zhang | Senior VP of the Group & GM of Frontage Shanghai |
Mr. Sudendra Rao Ph.D. | Senior Vice President of Human Resources - North America |
Dr. Wentao Zhang Ph.D. | Chief Strategy Officer at Frontage Laboratories |
Dr. John Kapeghian Ph.D. | Executive Vice President of Global Safety & Toxicology |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 24.5098 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.5993 |
Price-to-Sales TTM: | 0.7712 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 1657 |